Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Timing and durability of response to erenumab in patients with chronic migraine

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Symptomatic migraine: A systematic review to establish a clinically important diagnostic entity

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Treatment of medication overuse headache: Effect and predictors after 1 year-A randomized controlled trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Green Flags and headache: A concept study using the Delphi method

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. The chronobiology of migraine: a systematic review

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. PEARL study protocol: a real-world study of fremanezumab effectiveness in patients with chronic or episodic migraine

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Opening of BKCa channels causes migraine attacks: a new downstream target for the treatment of migraine

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Erenumab prevents the occurrence of migraine attacks and not just migraine days: Post-hoc analyses of a phase III study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Guidelines of the International Headache Society for clinical trials with neuromodulation devices for the treatment of migraine

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Stewart J Tepper
  • Sylvia Lucas
  • Messoud Ashina
  • Todd J Schwedt
  • Jessica Ailani
  • James Scanlon
  • Jan Klatt
  • Denise E Chou
  • Andrea Wang
  • Gabriel Paiva da Silva Lima
Vis graf over relationer

BACKGROUND: Erenumab is a human anti-calcitonin gene-related peptide receptor monoclonal antibody approved for migraine prevention. We sought to further assess the temporal patterns of response to erenumab in patients with chronic migraine (CM), specifically the onset and sustainability of monthly migraine day (MMD) response.

METHODS: This is a post hoc analysis of a 12-week, randomized, double-blind, placebo-controlled study of erenumab for migraine prevention in patients with CM (≥15 headache days/month, including ≥8 migraine days/month). Onset and sustainability were assessed according to MMD reduction from baseline, with the following response categories: responders (≥50% reduction), partial responders (≥30% and <50%), or nonresponders (<30%).

RESULTS: Among the erenumab 140 mg group (n = 187), 54.0% (101/187) achieved a response at any month during the study with a median time to onset of monthly response of 1 month. This improvement was maintained in most patients with continued treatment. An initial response was achieved at Month 1 by 28.3% (53/187) of patients; 69.8% (37/53) of whom maintained a response at Months 2 and 3. Although many patients responded early, some patients required longer treatment to achieve a response; 79.4% (27/34) of initial partial responders and 21.0% (21/100) of initial nonresponders subsequently achieved a response. Similar findings were observed for the erenumab 70mg group (n = 188).

CONCLUSION: A majority of erenumab-treated patients with CM who achieved an initial response at Month 1 sustained this benefit. Many patients responded later with continued treatment. Our data support recommendations to assess outcomes after ≥3 months of preventive treatment with erenumab in CM.

OriginalsprogEngelsk
Artikelnummer14193
TidsskriftHeadache
Vol/bind61
Udgave nummer8
Sider (fra-til)1255-1263
Antal sider9
ISSN0017-8748
DOI
StatusUdgivet - sep. 2021

ID: 67198634